Resurfacing an August move: Marico's Q1 FY26 revenue climbed 23% as India growth accelerated; raised Plix stake
Marico had reported Q1 FY26 consolidated revenue of Rs 3,259 crore, up 23.3% year on year, while net profit rose 8.2% to Rs 513 crore, in a disclosure from early August 2025. India revenue grew 27.2% and international revenue rose 12.9%. The company also increased its fully diluted stake in Plix maker Satiya Nutraceuticals to 60%.
What happened
Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India revenue. It increased its stake in Plix maker Satiya
Key facts
- Q1 FY26 consolidated net profit Rs 513 crore, up 8.2% YoY from Rs 474 crore
- Revenue from operations Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
- Total income Rs 3,315 crore, including Rs 56 crore other income
- Total expenses Rs 2,659 crore, versus Rs 2,075 crore
- India revenue Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
- International revenue Rs 764 crore, up 12.91% YoY from Rs 681 crore
- India PBT Rs 469 crore
- International PBT Rs 213 crore
- Marico raised its stake in Satiya Nutraceuticals to 60% on a fully diluted basis
Why this matters
Raising its Plix maker stake to 60% gives Marico control over a high-growth nutraceutical platform and strengthens its presence beyond core FMCG categories.
What to watch
- India volume growth versus price-led growth in the next quarterly update.
- Gross-margin and EBITDA-margin trend, especially given profit growth lagging revenue growth.
- Copra, edible-oil, crude-derivative and packaging-cost movements.
- Plix revenue growth, distribution expansion, profitability and the extent of consolidation-related costs.
- Advertising-and-promotion spend as a percentage of sales.
- International constant-currency growth, Bangladesh/Middle East demand and foreign-exchange impact.
- Management guidance on FY26 revenue growth, margin outlook and further wellness-category acquisitions.
- Increase Plix distribution, digital marketing and product launches across protein, wellness and lifestyle nutrition categories.
- Use majority ownership of Satiya Nutraceuticals to consolidate financials and pursue cross-selling through Marico’s retail, e-commerce and quick-commerce network.
- Sustain advertising and innovation spending in India to defend accelerated growth and premium market-share gains.
- Manage commodity exposure, pricing and pack-size architecture to protect gross margin if input costs rise.
- Prioritise international-market recovery and currency-risk management as India becomes a larger growth contributor.